Amneal Pharmaceuticals, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group reported 0% beneficial ownership of Amneal Pharmaceuticals Inc. following an internal realignment, with subsidiaries now reporting separately.
NASDAQ
Akram Mahesh has reported a beneficial ownership of 6.56% of Amneal Pharmaceuticals, Inc.'s Class A Common Stock as of March 31, 2025, through trusts managed by his wholly-owned Tattva Fiduciary Company.
NASDAQ
The Vanguard Group has filed a Schedule 13G, reporting a 5.02% beneficial ownership stake in Amneal Pharmaceuticals Inc., totaling 15,762,727 shares of common stock.
NASDAQ
SCHEDULE 13G/A: UBS Group AG Files Amended Schedule 13G for Amneal Pharmaceuticals, Disclosing Zero Beneficial Ownership
UBS Group AG has filed an amended Schedule 13G for Amneal Pharmaceuticals, Inc., reporting zero beneficial ownership of Class A Common Stock as of December 31, 2024, following its acquisition of Credit Suisse Group AG.